All In Vitro Testing articles
-
NewsExisting drug could target neuroinflammation across multiple brain disorders
Researchers at the University of Birmingham have identified the P2X7 receptor as a key driver of neuroinflammation in human brain tissue, raising the prospect of repurposing existing therapies to treat various brain conditions.
-
NewsThree-signal method converts blood B cells into germinal centre-like cells
Researchers at the University of Osaka have developed a streamlined laboratory method that uses just three sequentially delivered signals to convert naive B cells from human blood into cells closely resembling germinal centre B cells.
-
NewsMenin inhibitor KO-7246 shows β-cell regeneration in preclinical diabetes models
New preclinical data suggests that menin inhibitor KO-7246 can regenerate functional pancreatic β-cells and sustain improvements in blood glucose control across both Type 1 and Type 2 diabetes models.
-
NewsVaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
-
NewsKidney organoids reveal inflammation drives diabetic kidney disease
University of Washington researchers have used stem cell-derived kidney organoids to uncover inflammatory pathways that drive diabetic kidney disease.
-
NewsLiver cancer organoids used to screen 1,600 potential treatments
Researchers at the University of Basel have screened more than 1,600 compounds using a biobank of 35 hepatocellular carcinoma organoids, identifying drug combinations that show selective anti-tumour activity across biologically diverse liver cancers.
-
WebinarVLPs as serological tools for diagnostics and vaccine development
What makes VLPs so useful in diagnostics and vaccine development? Explore their manufacture, serological applications and use in capturing neutralising antibodies.
-
ArticleFast-tracking AI-designed binders with cell-free expression and SPR
AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
-
ArticleSix assay requirements every researcher using NAMs should know
As NAMs become more widely used in drug discovery, assays must meet the demands of more complex models. Discover six requirements for reliable, reproducible and biologically meaningful data.
-
NewsPatient-specific brain tumour chip models vascular drug barriers
A microfluidic chip combining patient-derived glioblastoma cells with their tumour vascular environment could give drug developers a more realistic preclinical model for predicting treatment response – and may help explain why genetically similar patients respond differently to the same therapy.
-
NewsMulti-target screening refines ADC development for cervical cancer
A large-scale transcriptomic study has pinpointed distinct cell-surface targets for antibody-drug conjugate development across cervical cancer subtypes, revealing how tissue-of-origin comparisons and subpopulation analysis can uncover targets missed by conventional screening approaches.
-
NewsTissue chips target immunotherapy toxicity prediction without animal models
Researchers at the University of Rochester have developed human cell-based tissue chips designed to predict serious immunotherapy toxicities, including cytokine release syndrome, and have secured entry into the FDA’s ISTAND pilot programme.
-
NewsTriple drug combination targets cancer and senescent cells simultaneously
A three-drug combination targeting shared metabolic vulnerabilities in cancer and senescent cells has improved physical performance and extended survival in aged mice, whilst avoiding the thrombocytopenia associated with existing navitoclax-based regimens.
-
WebinarMeeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
-
NewsTumour organoids may expand access to targeted cancer drugs
Two studies from Weill Cornell Medicine demonstrate that patient-derived tumour organoids can accurately replicate cancers long-term and incorporate immune microenvironments, offering new potential for personalised treatment selection.
-
NewsCrown Bioscience joins C-Path coalition advancing regulatory NAMs acceptance
Crown Bioscience has joined the Critical Path Institute’s New Approach Methodologies Developer Coalition, bringing patient-derived model expertise and biomarker capabilities to efforts aimed at establishing regulatory qualification frameworks for human-relevant research tools.
-
NewsVitronectin protein identified as key driver of lung scarring
Researchers from UTS and Monash University have identified vitronectin as a key protein driving abnormal lung scarring in idiopathic pulmonary fibrosis, opening a potential new avenue for therapeutic intervention in a disease with very few treatment options.
-
NewsMechanical forces key to realistic organ-on-chip laboratory models
A new review highlights how physical forces such as blood flow, breathing and tissue stiffness must be replicated alongside biochemical signals to produce physiologically accurate organoid and organ-on-chip models for disease research and drug testing.
-
ArticleOrgan chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
-
NewsXL20 drug candidate shields motor neurons from ALS-linked TDP-43 damage
A newly identified experimental compound, XL20, has demonstrated neuroprotective effects in mouse models and human motor neurons by targeting a conserved disease-linked region of TDP-43, a protein central to ALS pathology.